Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Fromm

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology and Therapeutics|November 28, 2008
Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal studyT Rau, H Wuttke, L M Michels, et al.
Circulation|December 16, 1998
Modulation by dietary salt of verapamil disposition in humansD Darbar, M F Fromm, S Dell'Orto, et al.
Pharmacogenetics|July 4, 2001
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsM Hitzl, S Drescher, H van der Kuip, et al.
The Journal of Clinical Investigation|February 7, 1998
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitorsR B Kim, M F Fromm, C Wandel, et al.
Clinical Pharmacology and Therapeutics|September 15, 2001
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion techniqueO von Richter, B Greiner, M F Fromm, et al.
The American Journal of Pathology|November 14, 2000
The effect of rifampin treatment on intestinal expression of human MRP transportersM F Fromm, H M Kauffmann, P Fritz, et al.
Clinical Pharmacology and Therapeutics|April 18, 2014
Response to "the effect of green tea with exceptionally high catechin content on nadolol plasma concentration"S Misaka, J Yatabe, F Müller, et al.
Clinical Pharmacology and Therapeutics|January 15, 2014
Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjectsS Misaka, J Yatabe, F Müller, et al.
Pharmaceutical Research|April 23, 1999
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoproteinR B Kim, C Wandel, B Leake, et al.
Clinical Pharmacology and Therapeutics|September 25, 2009
Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twinsA L Birkenfeld, J Jordan, U Hofmann, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology and Therapeutics|November 28, 2008
Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal studyT Rau, H Wuttke, L M Michels, et al.
Circulation|December 16, 1998
Modulation by dietary salt of verapamil disposition in humansD Darbar, M F Fromm, S Dell'Orto, et al.
Pharmacogenetics|July 4, 2001
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsM Hitzl, S Drescher, H van der Kuip, et al.
The Journal of Clinical Investigation|February 7, 1998
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitorsR B Kim, M F Fromm, C Wandel, et al.
Clinical Pharmacology and Therapeutics|September 15, 2001
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion techniqueO von Richter, B Greiner, M F Fromm, et al.
The American Journal of Pathology|November 14, 2000
The effect of rifampin treatment on intestinal expression of human MRP transportersM F Fromm, H M Kauffmann, P Fritz, et al.
Clinical Pharmacology and Therapeutics|April 18, 2014
Response to "the effect of green tea with exceptionally high catechin content on nadolol plasma concentration"S Misaka, J Yatabe, F Müller, et al.
Clinical Pharmacology and Therapeutics|January 15, 2014
Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjectsS Misaka, J Yatabe, F Müller, et al.
Pharmaceutical Research|April 23, 1999
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoproteinR B Kim, C Wandel, B Leake, et al.
Clinical Pharmacology and Therapeutics|September 25, 2009
Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twinsA L Birkenfeld, J Jordan, U Hofmann, et al.
Pageof 6